Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Takeda H, Nishikawa H, Osaki Y. The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers. Hepatobiliary Surg Nutr. 2018;7(6):490–491. doi:10.21037/hbsn.2018.08.06
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–511. doi:10.1038/ng.3252
   PubMed Web of Science ®Google Scholar
• Grinchuk OV, Yenamandra SP, Iyer R, et al. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol. 2018;12(1):89–113. doi:10.1002/1878-0261.12153
   PubMed Web of Science ®Google Scholar
• Bárcena C, Aran G, Perea L, et al. CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content. EBioMedicine. 2019;43:513–524. doi:10.1016/j.ebiom.2019.04.052
   PubMed Web of Science ®Google Scholar
• Gebe JA, Kiener PA, Ring HZ, Li X, Francke U, Aruffo A. Molecular cloning, mapping to human chromosome 1 q21-q23, and cell binding characteristics of Spalpha, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins. J Biol Chem. 1997;272(10):6151–6158. doi:10.1074/jbc.272.10.6151
   PubMed Web of Science ®Google Scholar
• Sanchez-Moral L, Ràfols N, Martori C, Paul T, Téllez É, Sarrias M-R. Multifaceted roles of CD5L in infectious and sterile inflammation. Int J Mol Sci. 2021;22(8):4076. doi:10.3390/ijms22084076
   PubMed Web of Science ®Google Scholar
• Sanjurjo L, Aran G, Roher N, Valledor AF, Sarrias M-R. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J Leukoc Biol. 2015;98(2):173–184. doi:10.1189/jlb.3RU0215-074R
   PubMed Web of Science ®Google Scholar
• Sanjurjo L, Aran G, Téllez É, et al. CD5L promotes M2 macrophage polarization through autophagy-mediated upregulation of ID3. Front Immunol. 2018;9:480. doi:10.3389/fimmu.2018.00480
   PubMed Web of Science ®Google Scholar
• Aran G, Sanjurjo L, Bárcena C, et al. CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78). FASEB J. 2018;32(7):3878–3891. doi:10.1096/fj.201700941RR
   PubMed Web of Science ®Google Scholar
• Wang H-W, Hsieh T-H, Huang S-Y, et al. Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics. 2013;14(1):736. doi:10.1186/1471-2164-14-736
   PubMed Web of Science ®Google Scholar
• Wang SM, Ooi LLPJ, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res. 2007;13(21):6275–6283. doi:10.1158/1078-0432.CCR-06-2236
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia H-L, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–10212. doi:10.1158/0008-5472.CAN-10-2607
   PubMed Web of Science ®Google Scholar
• Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3) - PubMed [Internet]; [ cited August 5 2020]. Available from: https://pubmed.ncbi.nlm.nih.gov/7698009/. Accessed November 22, 2021.
   Google Scholar
• Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 2011;44(3):291–299. doi:10.1111/j.1365-2184.2011.00752.x
   PubMed Web of Science ®Google Scholar
• Labbé DP, Sweeney CJ, Brown M, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017;23(22):7072–7083. doi:10.1158/1078-0432.CCR-17-0413
   PubMed Web of Science ®Google Scholar
• Wong N, Yeo W, Wong W-L, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124(3):644–652. doi:10.1002/ijc.23968
   PubMed Web of Science ®Google Scholar
• Schaefer I-M, Schweyer S, Kuhlgatz J. Chromosomal imbalances in primary hepatic carcinosarcoma. Hum Pathol. 2012;43(8):1328–1333. doi:10.1016/j.humpath.2011.11.007
   PubMed Web of Science ®Google Scholar
• Ding SF, Habib NA, Dooley J, Wood C, Bowles L, Delhanty JD. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer. 1991;64(6):1083–1087. doi:10.1038/bjc.1991.468
   PubMed Web of Science ®Google Scholar
• Raidl M, Pirker C, Schulte-Hermann R, et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol. 2004;40(4):660–668. doi:10.1016/j.jhep.2003.12.020
   PubMed Web of Science ®Google Scholar
• Nishida N, Nishimura T, Ito T, Komeda T, Fukuda Y, Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol. 2003;18(3):897–909. doi:10.14670/HH-18.897
   PubMed Web of Science ®Google Scholar
• Maehara N, Arai S, Mori M, et al. Circulating AIM prevents hepatocellular carcinoma through complement activation. Cell Rep. 2014;9:61–74.
   PubMed Web of Science ®Google Scholar
• Sanjurjo L, Amézaga N, Aran G, et al. The human CD5L/AIM-CD36 axis: a novel autophagy inducer in macrophages that modulates inflammatory responses. Autophagy. 2015;11(3):487–502. doi:10.1080/15548627.2015.1017183
   PubMed Web of Science ®Google Scholar
• Gray J, Chattopadhyay D, Beale GS, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9(1):271. doi:10.1186/1471-2407-9-271
   PubMed Web of Science ®Google Scholar
• Zhang D, Li Q, Qu H-C, Yu T, Liu Y-R. Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis. Genet Mol Res. 2015;14(3):9004–9012. doi:10.4238/2015.August.7.9
   PubMed Web of Science ®Google Scholar
• Dušenka R, Tomaškin R, Kliment J, et al. Polymorphism of the SRD5A2 gene and the risk of prostate cancer. Mol Med Rep. 2014;10(6):3151–3156. doi:10.3892/mmr.2014.2621
   PubMed Web of Science ®Google Scholar
• Francis A, Sarkar S, Pooja S, et al. SRD5A2 gene polymorphisms affect the risk of breast cancer. Breast. 2014;23(2):137–141. doi:10.1016/j.breast.2013.11.010
   PubMed Web of Science ®Google Scholar
• Moribe T, Iizuka N, Miura T, et al. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol. 2008;33(5):949–958.
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Sakaida I, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta. 2011;412(1–2):152–158. doi:10.1016/j.cca.2010.09.028
   PubMed Web of Science ®Google Scholar
• Tsunedomi R, Ogawa Y, Iizuka N, et al. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int J Oncol. 2010;36(1):205–212.
   PubMed Web of Science ®Google Scholar